Premium
Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
Author(s) -
Khalil Modar,
MorenoAjona David,
VillarMartínez María Dolores,
Greenwood Fiona,
Hoffmann Jan,
Goadsby Peter J.
Publication year - 2022
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.15364
Subject(s) - migraine , medicine , chronic migraine , adverse effect , tertiary care , audit , calcitonin gene related peptide , clinical trial , sumatriptan , pediatrics , receptor , management , neuropeptide , economics , agonist
Background and purpose Chronic migraine is a highly disabling primary headache disorder that is the most common diagnosis of patients seen at tertiary headache centres. Typical oral preventive therapies are associated with many limitations that impact their therapeutic utility. Erenumab was the first available calcitonin gene‐related peptide monoclonal antibody in the UK. It had proven efficacy in migraine prevention in clinical trials and limited real‐world data in tertiary settings. Methods We audited our first 92 patients ( n = 73 females) with severely disabling chronic migraine who were given monthly erenumab 70 mg sc for 6 months between December 2018 and December 2019. Results At 3 months, monthly migraine days were significantly reduced by a median of 4 days, and all other variables also showed significant improvement. The improvement was not affected by baseline analgesic use status. More than half of our patients experienced a clinically meaningful improvement in migraine days. No serious adverse events were reported. Conclusions Our real‐world data with erenumab demonstrate it is effective and well tolerated in managing patients with chronic migraine in a tertiary care setting.